66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study

{"title":"66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study","authors":"A.R. Filippi , M. R. García Campelo , J-B. Paoli , D. Kowalski , C. Bennati , P. Borghetti , D. Cortinovis , A. Delmonte , C. Genova , R. Mroz , S. Nawrocki , I. Toledano , G. Tonini , F. Agustoni , G. Wetherill , I. Diaz Perez , N. Georgoulia , R. Dziadziuszko","doi":"10.1016/j.iotech.2024.100809","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100809"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}